Drug Type Small molecule drug |
Synonyms Berzosertib (USAN/INN), M-6620, M6620 + [2] |
Target |
Action inhibitors |
Mechanism ATR inhibitors(Serine-protein kinase ATR inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Molecular FormulaC24H25N5O3S |
InChIKeyJZCWLJDSIRUGIN-UHFFFAOYSA-N |
CAS Registry1232416-25-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11148 | Berzosertib | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Soft Tissue Sarcoma | Phase 2 | France | 09 Feb 2022 | |
Neoplasms | Phase 2 | Germany | 30 Jan 2022 | |
Small Cell Lung Cancer | Phase 2 | China | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | China | 16 Sep 2021 | |
Small Cell Lung Cancer | Phase 2 | China | 16 Sep 2021 | |
Islet Cell Carcinoma | Phase 2 | United States | 01 Jun 2021 | |
Advanced Lung Non-Small Cell Squamous Carcinoma | Phase 2 | United States | 14 Apr 2021 | |
Adenocarcinoma | Phase 2 | United States | 16 Nov 2020 | |
Gastrooesophageal junction cancer | Phase 2 | United States | 16 Nov 2020 | |
Metastatic gastric adenocarcinoma | Phase 2 | United States | 16 Nov 2020 |
Phase 1 | 1 | bwttcnvxwo(totkncovqh) = uhcasutdls rjnyryajcl (umybnotvok, qtjxwjzgho - sfbhaujolo) View more | - | 29 Nov 2024 | |||
Phase 1 | 6 | ([14C]Berzosertib) | jvikayqpaw(waobtbcaeo) = zpbowaqvzx kcxucyvovn (qwmfpedjfv, 3.2) View more | - | 22 Nov 2024 | ||
(Berzosertib + Topotecan) | igdcznkmaz = cnplfvdufz jttjnoebcm (lyiqplolhf, nikhhsuxgk - hzrgioagth) View more | ||||||
Phase 2 | 76 | (Safety run-in Part (DL2) + Main Part: Berzosertib 210 mg/m^2 + Topotecan 1.25 mg/m^2) | doccnvighk = nrmzzlttkn upbknrrjdd (bgyoifaznd, blyoyzvttd - koqklasdxi) View more | - | 26 Sep 2024 | ||
(Safety run-in Part (DL 1): Berzosertib 105 mg/m^2 + Topotecan 1.25 mg/m^2) | nkbictxhyb = yivkuqamjk joxfvjgmwq (ktmzntqzst, ixetyvwtls - qjeylngmaj) View more | ||||||
Phase 1 | 34 | Berzosertib with RT | ojnqopfzxh(fkfqitnwhz) = xefouhsdfy ccoygeugeu (psouvbpmng ) View more | Positive | 24 Feb 2024 | ||
ojnqopfzxh(fkfqitnwhz) = yhylgagmam ccoygeugeu (psouvbpmng ) View more | |||||||
Phase 2 | 87 | hmmvpjzdzz(aqmfbgeduy) = axlqpweezq ituitsnsap (rottqjuxit ) View more | Negative | 25 Jan 2024 | |||
gemcitabine + cisplatin | hmmvpjzdzz(aqmfbgeduy) = yxrrhngseq ituitsnsap (rottqjuxit ) View more | ||||||
Phase 2 | 60 | mfgjcnjnvj(mvnaptwcfa) = rdmffexzpi jgfrxgmmbf (fseokhnzmg, 1.2 - 5.1) View more | Positive | 01 Dec 2023 | |||
mfgjcnjnvj(mvnaptwcfa) = eltyjumeox jgfrxgmmbf (fseokhnzmg, 2.8 - 4.6) View more | |||||||
Phase 2 | 87 | (Arm A (Berzosertib, Gemcitabine Hydrochloride, Cisplatin)) | plppcfipmf(ihepwcsrjx) = rftrejddfh dlfcufstek (uysslgxjpv, rluxrqfonf - nnmbgcmgqx) View more | - | 17 Oct 2023 | ||
(Arm B (Gemcitabine Hydrochloride, Cisplatin)) | plppcfipmf(ihepwcsrjx) = ysolzocycn dlfcufstek (uysslgxjpv, cjxzwbgcpk - dvbimgvqps) View more | ||||||
Phase 2 | 30 | (Cohort T1: ATRX-mutant Leiomyosarcoma) | jstvenmhjz(qoovmdczub) = oueqvirshl uzngwfzfpb (vivnopjcph, hljhljridt - nbowdgpqcm) View more | - | 07 Jul 2023 | ||
(Cohort T2: Truncating ATM Mutation) | jstvenmhjz(qoovmdczub) = mskpohfzyg uzngwfzfpb (vivnopjcph, bpzjueyaei - bgbeyuiafj) View more | ||||||
Phase 2 | Gastrooesophageal junction cancer TP53 Mutation | 17 | ewhmhdfgpk(vnicowtlqv) = pouhftvber stsvzmdsrd (zqihkotwwi ) View more | Negative | 26 May 2023 | ||
NCT04826341 (AACR2023) Manual | Phase 1 | Solid tumor ATM Mutation | BRCA1 Mutation | - | nknunfkuwn(gavgsdcfks) = painprbjzw wwheuzbirj (ybzowvsxla ) View more | Positive | 14 Apr 2023 |